Jane Wasman Purchases 20,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) Director Jane Wasman bought 20,000 shares of the firm's stock in a transaction on Friday, May 30th. The shares were acquired at an average cost of $1.69 per share, with a total value of $33,800.00. Following the purchase, the director now directly owns 30,400 shares of the company's stock, valued at approximately $51,376. This represents a 192.31% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

SELLAS Life Sciences Group Stock Down 0.9%

Shares of NASDAQ SLS traded down $0.02 on Thursday, reaching $1.59. 275,418 shares of the company's stock traded hands, compared to its average volume of 1,553,475. SELLAS Life Sciences Group, Inc. has a 12 month low of $0.77 and a 12 month high of $2.12. The business's 50 day simple moving average is $1.45 and its two-hundred day simple moving average is $1.25. The company has a market cap of $158.15 million, a price-to-earnings ratio of -2.28 and a beta of 2.25.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.04. Analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors have recently made changes to their positions in the company. Opus Capital Group LLC grew its holdings in shares of SELLAS Life Sciences Group by 5.5% during the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock valued at $248,000 after buying an additional 12,400 shares during the last quarter. Virtu Financial LLC boosted its holdings in SELLAS Life Sciences Group by 30.9% in the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock worth $58,000 after purchasing an additional 12,706 shares during the last quarter. Northern Trust Corp boosted its holdings in SELLAS Life Sciences Group by 33.6% in the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock worth $140,000 after purchasing an additional 33,878 shares during the last quarter. Geode Capital Management LLC boosted its holdings in SELLAS Life Sciences Group by 21.2% in the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock worth $763,000 after purchasing an additional 128,355 shares during the last quarter. Finally, Anson Funds Management LP boosted its holdings in SELLAS Life Sciences Group by 50.2% in the fourth quarter. Anson Funds Management LP now owns 1,192,266 shares of the company's stock worth $1,240,000 after purchasing an additional 398,431 shares during the last quarter. Hedge funds and other institutional investors own 17.38% of the company's stock.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.